
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2007

International Stem Cell Corporation

(Exact name of registrant as specified in its charter)

DELAWARE

(State or other Jurisdiction of
Incorporation)

0-51891

(Commission File Number)

20-4494098

(IRS Employer Identification No.)

**2595 Jason Court
Oceanside, CA**

(Address of Principal Executive Offices)

92056

(Zip Code)

Registrant's telephone number, including area code: **(760) 940-6383**

BTHC III, INC.

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On January 29, 2007 pursuant to a Certificate of Amendment filed with the Delaware Secretary of State, the Registrant changed its name to "International Stem Cell Corporation" and in connection therewith was issued the new trading symbol "ISCO". See the Press Release attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(a) *Financial statements of business acquired.*

(b) *Pro Forma Financial Information.*

(c) *Exhibits.*

Exhibit**Number****Description**

99.1

Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

International Stem Cell Corporation

Dated: January 29, 2006

By: /s/ Jeff Krstich

Name: Jeff Krstich

Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release

Contacts:

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
kaldrich@intlstemcell.com
Jeff Krstich, CEO
jkrstich@intlstemcell.com
760-940-6383

Investor Relations:

Capital Group Communications, Inc.
Abigail Bruce/George Carpenter
abigail@capitalgc.com
george@capitalgc.com
415-332-7200 Office
415-332-7201 Fax

Media Relations:

The Orbach Company, Inc.
Nevena Orbach
818-904-0500
nevena@orbachco.com

**BTHC III, INC., (BTHC.OB) CHANGES ITS NAME AND STOCK
SYMBOL TO INTERNATIONAL STEM CELL CORPORATION
(ISCO.OB)**

Oceanside, California, January 29, 2007– BTHC III, Inc (BTHC.OB) has changed its name and stock symbol to International Stem Cell Corporation (OTCBB: ISCO.OB). The announcement was made today by Kenneth Aldrich, Chairman of the Board of International Stem Cell Corporation.

The name and stock symbol change became effective and the shares commenced trading under its new name and stock symbol “ISCO.OB” with NASDAQ’s Over-The-Counter Bulletin Board at market open on January 29, 2007.

ABOUT INTERNATIONAL STEM CELL CORPORATION:

International Stem Cell is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO’s objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO is currently developing human stem cells, techniques to cause those stem cells to be “differentiated” into the specific cell types required for transplant, and manufacturing protocols to produce the cells without contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. For more information, visit the ISCO website at: www.intlstemcell.com.

FORWARD LOOKING STATEMENT

This news release contains forward-looking statements relating to the business of ISCO and its subsidiary. Investors are cautioned that such forward-looking statements regarding ISCO, its technology, clinical development and potential applications, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. International Stem Cell Corporation disclaims any intent or obligation to update these forward-looking statements.

